Drug Type CAR-T |
Synonyms- |
Target |
Mechanism CD38 modulators(Lymphocyte differentiation antigen CD38 modulators), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Refractory acute myeloid leukemia | Phase 2 | CN | 01 Jul 2017 | |
Relapsing acute myeloid leukemia | Phase 2 | CN | 01 Jul 2017 |
NCT04351022 (EBMT2023) Manual | Phase 1/2 | 20 | oeieipxkgg(zutoarpivd) = gpnztpekni gdyzwgdpyx (myvtqdpcja ) View more | Positive | 26 Apr 2023 | ||
NCT04351022 (ASH2020) Manual | Phase 1/2 | 6 | ujsayobaoh(ncyavurlsm) = mhrqszbhuf krfufnqujn (gkurazemkp ) View more | Positive | 05 Nov 2020 |